Asset Advisors Corp reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 0.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 91,207 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Asset Advisors Corp’s holdings in Pfizer were worth $3,211,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Swiss National Bank boosted its position in shares of Pfizer by 8.4% in the second quarter. Swiss National Bank now owns 18,298,389 shares of the biopharmaceutical company’s stock worth $644,286,000 after buying an additional 1,412,800 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Pfizer by 5.0% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 232,200 shares of the biopharmaceutical company’s stock worth $8,176,000 after buying an additional 11,030 shares during the last quarter. RFG Advisory Group LLC boosted its position in shares of Pfizer by 16.4% in the second quarter. RFG Advisory Group LLC now owns 17,031 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 2,394 shares during the last quarter. Lincoln Capital LLC boosted its position in shares of Pfizer by 1.1% in the second quarter. Lincoln Capital LLC now owns 8,443 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 94 shares during the last quarter. Finally, Gratus Capital LLC purchased a new position in shares of Pfizer during the second quarter worth $1,613,000. Hedge funds and other institutional investors own 69.65% of the company’s stock.
Pfizer Inc. (NYSE:PFE) traded up 0.30% during midday trading on Wednesday, reaching $33.93. The company’s stock had a trading volume of 10,482,626 shares. The firm has a 50-day moving average price of $34.60 and a 200 day moving average price of $34.02. The stock has a market capitalization of $205.81 billion, a price-to-earnings ratio of 30.08 and a beta of 0.87. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share. Equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.55%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio is currently 95.24%.
A number of research analysts recently weighed in on the company. Bank of America Corp. reiterated a “buy” rating and issued a $40.00 target price on shares of Pfizer in a report on Tuesday. Sanford C. Bernstein restated an “outperform” rating on shares of Pfizer in a research note on Monday. Jefferies Group reduced their price objective on Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Tuesday, September 13th. Argus restated a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research note on Sunday, August 28th. Finally, Piper Jaffray Cos. set a $54.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 23rd. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Pfizer presently has a consensus rating of “Buy” and a consensus price target of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.